Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Competitors
The companies most similar to Amneal Pharmaceuticals, Inc. Class A Common Stock are Lantheus Holdings (LNTH), Elanco Animal Health (ELAN) and Neurocrine Biosciences (NBIX). Amneal Pharmaceuticals, Inc. Class A Common Stock trades at 21.4x earnings, against a median of 18.4x for the 11 of these companies with a P/E. By market cap, Amneal Pharmaceuticals, Inc. Class A Common Stock ranks 5th of the 13 companies on this page; Neurocrine Biosciences (NBIX) is the largest at $16.94B.
Peer Comparison
AMRX's ROIC of 11.6% is above the peer median of 7.9%, and its revenue growth of 10.0% is below the median of 13.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $7.45B | 21.4x | 2.2x | 4.2% | 11.6% | 10.0% | 0.00% |
| Lantheus Holdings Inc (LNTH) | $6.64B | 17.9x | 4.5x | 17.3% | 14.8% | 1.5% | 0.00% |
| Elanco Animal Health (ELAN) | $13.39B | 23.2x | 2.6x | -2.9% | 1.6% | 11.3% | 0.00% |
| Neurocrine Biosciences Inc (NBIX) | $16.94B | 18.4x | 4.5x | 19.0% | N/A | 41.2% | 0.00% |
| Kiniksa Pharmaceuticals Ltd (KNSA) | $7.57B | 72.5x | 7.8x | 11.6% | N/A | 58.1% | 0.00% |
| Indivior PLC Ordinary Shares (INDV) | $4.28B | 6.6x | 2.4x | 32.8% | 109.0% | 13.4% | 0.00% |
| Amphastar P (AMPH) | $1.25B | 10.3x | 1.7x | 13.3% | 7.9% | 8.2% | 0.00% |
| Hims Hers Health Inc (HIMS) | $4.62B | N/A | 1.5x | -6.7% | -11.1% | 48.6% | 0.00% |
| Xeris Pharmaceuticals Inc (XERS) | $3.04B | 139.2x | 8.2x | -1.8% | 15.5% | 44.2% | 0.00% |
| Dr. Reddy’s Laboratories Ltd ADR (RDY) | $12.29B | 39.6x | 3.5x | 8.5% | 5.7% | -1.5% | 0.44% |
| Bausch Health Companies Inc (BHC) | $3.13B | 1.7x | 0.3x | -7.6% | 6.3% | 9.7% | 0.00% |
| Eton Pharmaceuticals Inc (ETON) | $1.84B | 36.7x | 13.0x | 35.3% | 37.0% | 157.9% | 0.00% |
| Supernus Pharmaceuticals, Inc. (SUPN) | $1.52B | 12.7x | 2.0x | 32.8% | N/A | 13.4% | 0.00% |
| Peer median | $4.45B | 18.4x | 3.0x | 12.4% | 7.9% | 13.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Amneal Pharmaceuticals, Inc. Class A Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Drug Manufacturers - Specialty & Generic.
| Company | About | Peers |
|---|---|---|
| Lantheus Holdings Inc (LNTH) | Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment... | LNTH competitors |
| Elanco Animal Health (ELAN) | Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. | ELAN competitors |
| Neurocrine Biosciences Inc (NBIX) | Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological... | NBIX competitors |
| Kiniksa Pharmaceuticals Ltd (KNSA) | Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical... | KNSA competitors |
| Indivior PLC Ordinary Shares (INDV) | Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence... | |
| Amphastar P (AMPH) | Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation... | AMPH competitors |
| Hims Hers Health Inc (HIMS) | Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. | HIMS competitors |
| Xeris Pharmaceuticals Inc (XERS) | Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. | XERS competitors |
| Dr. Reddy’s Laboratories Ltd ADR (RDY) | Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India. | RDY competitors |
| Bausch Health Companies Inc (BHC) | Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical... | BHC competitors |
| Eton Pharmaceuticals Inc (ETON) | Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. | ETON competitors |
| Supernus Pharmaceuticals, Inc. (SUPN) | Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases... | SUPN competitors |
Frequently Asked Questions About AMRX
Who are Amneal Pharmaceuticals, Inc. Class A Common Stock's main competitors?
The companies most similar to Amneal Pharmaceuticals, Inc. Class A Common Stock include Lantheus Holdings (LNTH), Elanco Animal Health (ELAN), Neurocrine Biosciences (NBIX), Kiniksa Pharmaceuticals (KNSA) and Indivior PLC Ordinary Shares (INDV), listed from the closest match.
Who is Amneal Pharmaceuticals, Inc. Class A Common Stock's biggest competitor?
Neurocrine Biosciences (NBIX) is the largest of the similar companies at $16.94B; Lantheus Holdings (LNTH) is the closest match by business profile, size, sector and industry.
How does AMRX stock compare with its competitors?
AMRX's P/E is 21.4x against a peer median of 18.4x; its P/S is 2.2x against a peer median of 3.0x; its net margin is 4.2% against a peer median of 12.4%.
Which of Amneal Pharmaceuticals, Inc. Class A Common Stock's competitors pays a higher dividend?
Amneal Pharmaceuticals, Inc. Class A Common Stock pays no dividend. Dr. Reddy’s Laboratories Ltd ADR (RDY) has a higher forward dividend yield; Dr. Reddy’s Laboratories Ltd ADR (RDY) has the highest at 0.44%.
Is Amneal Pharmaceuticals, Inc. Class A Common Stock bigger than its competitors?
No. Amneal Pharmaceuticals, Inc. Class A Common Stock is 5th by market cap among the 13 companies on this page; the largest is Neurocrine Biosciences (NBIX) at $16.94B.
AMRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors